Loading field map
Health financing is the subfield of global health concerned with how money is raised, pooled, and spent to purchase health services. It addresses a deceptively simple set of questions: Where does funding for health come from? How is that funding combined and managed? And how is it used to buy or provide care? The answers determine whether people can obtain medical treatment without financial hardship, whether health systems have the resources to function, and whether those resources are used efficiently and fairly. Because health care is costly, unpredictable, and widely considered a social good, every country must design arrangements that balance competing goals—and no arrangement fully satisfies all of them.
Three functions form the analytical backbone of the field: revenue collection, pooling, and purchasing. Revenue collection is the process of raising funds from households, employers, and external sources. Pooling refers to the accumulation of these funds so that the financial risk of illness is shared across a population rather than borne by individuals at the moment of sickness. Purchasing is the process of transferring pooled funds to health care providers—hospitals, clinics, doctors, drug suppliers—in ways that influence what services are delivered, to whom, and at what quality.
These functions are studied because health care differs from most goods in ways that create predictable market failures. Illness is unpredictable, so individuals cannot reliably budget for care. The cost of serious treatment can exceed most households' assets, so without risk-sharing, illness causes impoverishment. Patients also know less than providers about what care they need, which can lead to unnecessary, ineffective, or harmful treatment when financial incentives reward providers for doing more. And because many health interventions—vaccination, sanitation, treatment of contagious disease—benefit people other than the patient, private purchase alone will underprovide them. Health financing is therefore not merely an accounting question; it is the set of institutional arrangements that respond to these failures.
The central normative concern of the field is universal health coverage (UHC): ensuring that all people can use needed health services without suffering financial hardship. UHC is usually analyzed along three dimensions—population coverage (who is entitled), service coverage (which services are included), and financial protection (how much people pay out of pocket). Health financing research and practice largely revolve around measuring these dimensions, explaining why countries fall short of them, and designing financing systems that improve them.
The most consequential distinction in the field is between two broad ways of organizing revenue collection and pooling. The first is social health insurance (SHI), also called Bismarckian financing after its nineteenth-century German origins. Under SHI, contributions are deducted from wages, usually split between employees and employers, and channeled to sickness funds—nonprofit insurers that may be organized by region, occupation, or company. Entitlement is tied to contribution, though dependents are typically covered as well. The second is the tax-funded or Beveridgean model, named for the British postwar settlement, in which general government revenue—income taxes, corporate taxes, value-added taxes—finances health care, and entitlement is based on residence or citizenship rather than contribution. Many countries blend the two, and the categories are ideal types rather than rigid boxes, but the distinction remains analytically important because the two models raise money differently, create different incentives, and produce different patterns of coverage.
Social health insurance is praised for creating a stable funding stream that is earmarked for health and insulated from annual budget politics. Because contributions are linked to payroll, the system is typically financed by formal-sector workers, which can be a strength in industrialized economies and a weakness in countries where most people work informally. It also makes the link between paying and benefiting visible, which can build political support but can also fragment the risk pool if different funds cover different income groups. Tax-funded systems, by contrast, can spread risk across the entire population in a single pool and can be more progressive if taxes are progressive. Their weakness is that health competes with all other public priorities in the budget, and funding can be cut in fiscal downturns. Both systems must solve the same purchasing problem: how to pay providers in ways that encourage accessible, high-quality care without uncontrolled cost inflation.
Historically, these two models emerged as rival national solutions, and debates about their relative merits dominated twentieth-century health policy. In the contemporary field, most analysts treat the choice as contingent rather than ideological. Countries with large informal workforces have found payroll-based SHI difficult to sustain, because contributions from formal workers subsidize the informal sector or because informal workers cannot be compelled to contribute. Low- and middle-income countries have therefore often combined general tax funding with fragmented insurance schemes, creating the hybrid arrangements now common across Asia, Africa, and Latin America. The intellectual movement has been away from defending one model and toward asking which combination of instruments achieves UHC under given economic and political conditions.
The negative reference point for most health financing analysis is direct out-of-pocket payment: the patient paying the provider at the point of service. This is the oldest and most universal form of health financing, and it remains the dominant one in many low-income settings. Its defining feature is that no pooling occurs—the sick bear the full cost of their care. Out-of-pocket payment is associated with two harms that health financing seeks to prevent: forgone care, in which people who cannot pay go untreated, and catastrophic health expenditure, in which households that do seek care must cut other essential spending such as food, education, or housing, or must sell assets and borrow.
Health financing research has documented these harms across many countries and used them as the primary empirical justification for expanding prepaid financing. The field distinguishes prepayment from out-of-pocket spending: prepayment, whether through taxes or insurance, separates the financial risk of illness from the moment of care and is considered a necessary condition for financial protection. However, out-of-pocket payment survives in all systems to some degree, through user fees, copayments, deductibles, and the purchase of services not covered by the pooled system. A central debate concerns whether small out-of-pocket charges are acceptable tools for discouraging unnecessary care and raising modest revenue, or whether they inevitably deter necessary care and punish the poor. Most current evidence suggests that the harms of user fees outweigh their benefits at the margin, and recent policy has moved toward removing fees for high-priority services such as maternal and child health care, though the practice remains widespread.
A distinct financing arrangement, historically important in low-income countries, is community-based health insurance (CBHI). These are voluntary, locally organized schemes in which members pay small premiums and receive partial coverage for a defined set of services, typically at a nearby health facility. CBHI emerged in the late twentieth century as a response to the exclusion of rural and informal-sector populations from formal insurance. Its advocates argued that it built on local solidarity, could adapt to local needs, and was administratively feasible where state capacity was weak. Its critics, and eventually much of the evidence, found that CBHI faced severe limits: premiums were too low to cover expensive care, risk pools were small and could not withstand large claims, adverse selection drove up costs, and voluntary enrollment excluded the poorest, who could not afford even small premiums. Many CBHI schemes therefore covered only routine, low-cost care and left the risks that actually caused impoverishment—hospitalization and chronic disease—uncovered.
The lesson drawn by the mainstream of the field was not that pooling is wrong but that voluntary, small-scale pooling cannot achieve universal coverage or robust financial protection. The influential recommendation, associated with the World Health Organization and much academic research, is that countries should move toward mandatory, large, and ideally single risk pools, financed through general taxation or compulsory contributions, with explicit subsidies for the poor. CBHI has not disappeared—it still operates in many rural areas—but the direction of travel has been to integrate such schemes into national systems or replace them with tax-financed coverage. This trajectory illustrates a general finding of the subfield: the scale and compulsion of pooling matter more for achieving UHC than the particular institutional label attached to it.
In the poorest countries, domestic financing is often insufficient to fund even a basic package of services, and external financing—development assistance for health—plays a substantial role. External funds come from bilateral donors, multilateral organizations such as the World Bank and the Global Fund to Fight AIDS, Tuberculosis and Malaria, philanthropic foundations, and nongovernmental organizations. These funds have historically been channeled in two ways: through general budget support, in which donors give money to the government without specifying its use, and through disease-specific, vertical programs targeted at particular conditions such as HIV/AIDS, tuberculosis, malaria, and immunization.
The vertical-versus-horizontal debate has structured much of the discussion of external financing. Vertical programs have achieved major gains in specific diseases by concentrating funding, expertise, and accountability on single conditions. But they also distort health systems: they attract health workers away from general services, create parallel supply chains and data systems, and leave common conditions outside the funded priorities underresourced. The current consensus is not that vertical programs are wholly good or bad but that they must be deliberately linked to broader health system strengthening. A related issue is fragmentation: when many donors fund many separate projects, transaction costs rise, coordination fails, and the government's ability to plan its own health sector is weakened. The field therefore studies mechanisms for harmonizing donor behavior, such as pooled funding arrangements and sector-wide approaches, though actual donor coordination remains partial and contested in practice.
A further concern is the sustainability of external financing. Because donor funding is volatile and often short-horizon, countries that rely on it face the risk of sudden shortfalls. The subfield analyzes how external funds interact with domestic politics and fiscal capacity—for example, whether easy external money displaces government health spending rather than supplementing it, a phenomenon sometimes called fungibility or fiscal displacement. Research on this question has produced mixed findings, but the practical implication is that donors and governments must explicitly plan the transition from external to domestic financing, a process now underway in several middle-income countries as donors withdraw and domestic economies grow.
If revenue collection and pooling determine how much money is available and how risk is shared, purchasing determines what that money actually achieves. The field distinguishes passive purchasing, in which the payer merely reimburses whatever services providers deliver, from strategic purchasing, in which the payer deliberately shapes provider behavior—for efficiency, quality, equity, and responsiveness—through the design of payment methods, contracts, and accountability arrangements. The shift toward strategic purchasing is one of the clearest recent movements in the subfield.
Provider payment methods are the central instruments of purchasing, and each creates distinct incentives. Global budgets pay a facility a fixed sum for a period, giving providers an incentive to control costs but risking underprovision and long waiting times. Fee-for-service pays per procedure or visit, rewarding volume and enabling access but creating incentives for unnecessary care and cost escalation. Capitation pays a fixed amount per enrolled person for a defined period, encouraging efficiency and prevention but risking risk-selection and skimping on services. Case-based payment, such as diagnosis-related groups (DRGs), pays a fixed amount per treated case, creating incentives to admit more patients and discharge them early while discouraging unnecessary procedures within each admission. Salary-based payment of doctors reduces their incentive to overprovide but can reduce effort and productivity.
No payment method dominates on all criteria, and the field has therefore moved toward understanding payment systems as packages that must balance incentives. A common pattern is mixed payment: a base capitation or budget to cover fixed costs, with some fee-for-service elements to protect access, and with quality bonuses or penalties to correct perverse incentives. Recent attention has also focused on value-based purchasing, which attempts to reward outcomes rather than volume—paying for successful treatment, patient improvement, or adherence to evidence-based protocols. These approaches remain experimental and face serious measurement difficulties: health outcomes are hard to attribute to a single provider, and tying payment to risk-adjusted outcomes can punish providers who serve the sickest patients unless the risk adjustment is sophisticated and fair.
An important body of work in the subfield analyzes why health financing systems look the way they do. This political economy perspective asks not only what financing arrangement is optimal but why countries adopt some arrangements and resist others. Health financing reform is inherently redistributive: it takes resources from some groups and gives benefits to others, so it generates winners and losers. Tax-funded systems require the better-off to subsidize the poor and the healthy to subsidize the sick. Social health insurance requires formal-sector workers and employers to accept payroll deductions. Expanding coverage requires raising revenue somewhere, and every revenue source has powerful constituencies behind it.
This perspective helps explain empirical regularities that purely technical analysis cannot. Countries with strong, centralized states have more easily implemented tax-funded systems. Countries with large formal labor markets and organized labor have historically built SHI. Countries with weak state capacity have often ended up with fragmented mixes and high out-of-pocket spending, not because policymakers chose these outcomes but because no coalition had both the interest and the power to impose a better one. The politics of health financing is not a separate topic from the economics; it determines which economically rational reforms are feasible, and it explains why the same policy instruments succeed in one context and stall in another.
Health financing is also defined by its empirical methods. The field measures revenue collection through national health accounts, which track the flow of funds from financing sources to financing schemes to providers. It measures financial protection through indicators such as the incidence of catastrophic health expenditure—out-of-pocket spending exceeding a threshold share of household income or consumption—and the incidence of impoverishment from medical spending. It measures coverage through household surveys that ask whether people were able to obtain services when needed and whether they paid for them. These measures are the basis for cross-country comparison and for tracking progress toward UHC.
A recurrent finding of this measurement literature is that the amount a country spends on health matters less than how the spending is organized. Some countries with moderate spending achieve near-universal coverage and strong financial protection, while others with similar or higher spending leave large shares of the population paying out of pocket. The organizing structure of financing—whether risk pools are large and mandatory, whether the poor are explicitly subsidized, whether purchasing is strategic—explains much of this variation. The field's policy conclusions therefore emphasize institutional design over spending levels, though adequate spending remains a necessary condition that many poor countries have yet to meet.
The contemporary landscape of health financing is shaped by several durable trends and unresolved debates. Universal health coverage has become the dominant international framework since the early 2010s, endorsed by the United Nations and embodied in the Sustainable Development Goals. In practice, this has shifted attention from narrow disease programs to system-wide financing reform. Many countries are in the midst of transitions—from out-of-pocket to prepaid systems, from fragmented schemes to unified pools, from passive to strategic purchasing—and the field studies these transitions comparatively, asking which sequencing and institutional choices succeed.
A major open set of questions concerns the fiscal sustainability of health systems in aging societies. As populations age, the burden of chronic disease rises, and the demand for long-term care grows. Health spending as a share of national income has risen across high-income countries, and health financing research increasingly asks what ceiling, if any, exists on health spending, whether efficiency gains can offset demographic pressure, and how health care should be rationed when demand exceeds available funds. These questions are fundamentally about the limits of all known financing mechanisms rather than about choosing among them.
Another frontier is the integration of digital technologies. Telemedicine, mobile payment platforms, and electronic health records change how services are purchased and how funds are tracked. Digital payment methods can reduce leakage and fraud in some settings, and data systems can improve the accountability of providers. But these tools raise new governance problems—data privacy, concentration of market power among technology firms, and the risk that digital systems replicate rather than reduce existing inequities. Health financing is absorbing these developments without yet having definitive answers about their system-level effects.
A third open question is how to extend coverage to the informal sector in low- and middle-income countries. This is the single largest practical problem facing the field: most of the world's poor work outside formal employment, cannot be taxed through payroll deductions, and have irregular incomes that make premium collection difficult. Approaches include subsidizing their enrollment in national schemes from general tax revenue, tying enrollment to other government services, using mobile money for premium collection, and simplifying benefit packages to reduce cost. None of these has been scaled to fully solve the problem, and the question of whether universal coverage is achievable in low-income settings within current financing instruments remains genuinely open.
Health financing is thus not a settled technical discipline but an evolving field organized around a stable set of functions—raising, pooling, and spending money for health—and a persistent normative commitment to protecting people from the financial consequences of illness. Its major internal debates are about which institutional arrangements perform these functions well, for whom, and under what conditions. The durable achievement of the field is to have shown that health system performance is not simply a matter of money but of how money is organized, and to have equipped policymakers and researchers with a shared analytical language for asking that question rigorously.